Correlation Between Achilles Therapeutics and Cyclerion Therapeutics

Can any of the company-specific risk be diversified away by investing in both Achilles Therapeutics and Cyclerion Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Achilles Therapeutics and Cyclerion Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Achilles Therapeutics PLC and Cyclerion Therapeutics, you can compare the effects of market volatilities on Achilles Therapeutics and Cyclerion Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Achilles Therapeutics with a short position of Cyclerion Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Achilles Therapeutics and Cyclerion Therapeutics.

Diversification Opportunities for Achilles Therapeutics and Cyclerion Therapeutics

-0.55

Correlation Coefficient

Achilles Therapeutics  Cyclerion Therapeutics

Excellent diversification

The 3 months correlation between Achilles and Cyclerion is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Achilles Therapeutics PLC and Cyclerion Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyclerion Therapeutics and Achilles Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Achilles Therapeutics PLC are associated (or correlated) with Cyclerion Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyclerion Therapeutics has no effect on the direction of Achilles Therapeutics i.e., Achilles Therapeutics and Cyclerion Therapeutics go up and down completely randomly.

Pair Corralation between Achilles Therapeutics and Cyclerion Therapeutics

Given the investment horizon of 90 days Achilles Therapeutics PLC is expected to generate 0.37 times more return on investment than Cyclerion Therapeutics. However, Achilles Therapeutics PLC is 2.69 times less risky than Cyclerion Therapeutics. It trades about 0.16 of its potential returns per unit of risk. Cyclerion Therapeutics is currently generating about 0.02 per unit of risk. If you would invest  71.00  in Achilles Therapeutics PLC on August 31, 2024 and sell it today you would earn a total of  36.00  from holding Achilles Therapeutics PLC or generate 50.7% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Achilles Therapeutics PLC  vs.  Cyclerion Therapeutics

Achilles Therapeutics PLC

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Cyclerion Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Cyclerion Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating fundamental indicators, Cyclerion Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Achilles Therapeutics and Cyclerion Therapeutics

The main advantage of trading using opposite Achilles Therapeutics and Cyclerion Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Achilles Therapeutics position performs unexpectedly, Cyclerion Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will offset losses from the drop in Cyclerion Therapeutics' long position.

The idea behind Achilles Therapeutics PLC and Cyclerion Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.